Drug Approval | November 14, 2025
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Venus Remedies now has 29 active product approvals in Vietnam alone
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Subscribe To Our Newsletter & Stay Updated
